Diagnostics (Mar 2024)

Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease

  • Helena Colvee-Martin,
  • Juan Rayo Parra,
  • Gabriel Antonio Gonzalez,
  • Warren Barker,
  • Ranjan Duara

DOI
https://doi.org/10.3390/diagnostics14070704
Journal volume & issue
Vol. 14, no. 7
p. 704

Abstract

Read online

An improved understanding of the pathobiology of Alzheimer’s disease (AD) should lead ultimately to an earlier and more accurate diagnosis of AD, providing the opportunity to intervene earlier in the disease process and to improve outcomes. The known hallmarks of Alzheimer’s disease include amyloid-β plaques and neurofibrillary tau tangles. It is now clear that an imbalance between production and clearance of the amyloid beta protein and related Aβ peptides, especially Aβ42, is a very early, initiating factor in Alzheimer’s disease (AD) pathogenesis, leading to aggregates of hyperphosphorylation and misfolded tau protein, inflammation, and neurodegeneration. In this article, we review how the AD diagnostic process has been transformed in recent decades by our ability to measure these various elements of the pathological cascade through the use of imaging and fluid biomarkers. The more recently developed plasma biomarkers, especially phosphorylated-tau217 (p-tau217), have utility for screening and diagnosis of the earliest stages of AD. These biomarkers can also be used to measure target engagement by disease-modifying therapies and the response to treatment.

Keywords